Navigation Links
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
Date:5/27/2009

ive medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.us.novartis.com.

References

  1. Arnold R, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. Abstract # 4508. American Society of Clinical Oncology 2009 Annual Meeting, Orlando, FL.
  2. Kloppel G, Perren A, Heitz PU The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification. Ann. of the New York Acad of Sci. 2006 Jan 16 2005;1014:13-27.
  3. Chen L, et al. Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). Abstract # 4587. American Society of Clinical Oncology 2009 Annual Meeting, Orlando, FL. Abstract #510. American Society of Clinical Oncology 2009 Annual Meeting, Orlando, FL.
  4. American Cancer Society. How is Liver Cancer Treated? Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_2_4X_How_Is_Liver_Cancer_Treated_25.asp?rnav=cri. Accessed April 2009.
  5. American Can
    '/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
2. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
3. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
4. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
5. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
6. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
7. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
8. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
9. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
10. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
11. Video: Answer to Curing a Failing Heart May Exist in Bodys Own Do-It-Yourself Repair Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)...  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... chronic pain, today announced the appointment of several ... panel of experts will provide support for planning ... the company pipeline of novel investigational therapies to ... range of areas including opioid receptors, addiction, psychiatry, ...
(Date:3/5/2015)... -- LUNGevity Foundation, the nation,s leading lung cancer ... approval of Bristol Myers Squibb,s new immunotherapy drug ... another critical new treatment option to fight lung ... own immune system to fight cancerous cells. Importantly, ... with squamous cell lung cancer, a population for ...
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... the "Japan Pharma Outlook 2015: Year to Watch ... Initiatives" report to their offering. ... from April -2014 (Annexure 1) is a ... - whether generic or innovator. The most of the ...
Breaking Medicine Technology:Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3
... , MISSISSAUGA, Ontario , June 18 CardioGenics ... Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of ... at http://www.cardiogenics.com/ataglance/ataglance.pdf , ... The 2-page profile was prepared by Redington, Inc., ...
... June 18 Watson Pharmaceuticals, Inc. (NYSE: ... that Watson management will provide an overview and update of ... Conference on Wednesday, June 23, 2010 at ... Boston . The presentation will be webcast live and can ...
Cached Medicine Technology:New Corporate Profile Posted On CardioGenics' Website 2Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference 2
(Date:3/6/2015)... 06, 2015 As the Mayo Clinic's ... discussed, Ford & Associates Nationwide Legal Services, A.P.C., comments ... filed lawsuit: Verduzco v. Daiichi Sankyo, Inc., Case No. ... , “In light of a recently filed lawsuit, ... to evaluate and explore the Mayo Clinic's Benicar case ...
(Date:3/5/2015)... From Oct. 5-10, Mumbai, India will serve as ... These dates include the following activities:, ... October 6: Conference Day 1, ending with a Fashion ... 2, ending with Local Entertainment and Dinner , ... Materials Meetings , October 9-10: Textiles in India ...
(Date:3/5/2015)... The global digital PCR (dPCR) and qPCR market is ... from 2014 to 2019. , The global digital PCR (dPCR) and ... from 2014 to 2019. Although the mature markets such as the ... PCR (dPCR) and qPCR market the Asia-Pacific region is expected to ... The growth of the digital PCR (dPCR) and qPCR market is ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 This ... formaldehyde in low-cost laminate flooring products, initiating ... manufacturer of eco-friendly building materials made primarily from ... by testing all their flooring products for volatile ... laboratory Benchmark International (BMH). Results from ...
(Date:3/5/2015)... March 05, 2015 AxoGen, Inc. ... on the peripheral nerve repair market, reported record revenue ... 31, 2014 compared to $2.98 million in the year-ago ... growth strategies. , “Our strong fourth quarter revenue ... nerve repair products which is driving increased surgeon adoption ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4
... , HOFFMAN ESTATES, Ill., July 16 ... America,s top medical institutions in the annual America,s Best Hospitals list published ... magazine. St. Alexius Medical Center was ranked among the top 50 hospitals ... , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090716/CG47487 ) ...
... NATICK, Mass., July 16 Boston Scientific Corporation (NYSE: ... from the U.S. Food and Drug Administration (FDA) to market ... drug-eluting stent (DES) designed for long lesions. At 38 ... option that can potentially reduce the number of stents used ...
... , PEKIN, Ill., July 16 ... of prescription foot and ankle orthoses and accompanying high technology ... award, which is given annually by the national Department of ... employment opportunities and support to veterans. , ...
... WALTHAM, Mass., July 16 According to Millennium ... intelligence, the fat reduction device market will experience the highest ... MRG,s European Markets for Body Contouring Devices 2009 ... fueled by physician adoption of newer modalities like transdermal ultrasound ...
... , , FRANKLIN, Mass., ... a company focused on innovative cardiac and vascular medical device-based ... Cardiac Angiography in Renally Impaired Patients (CARE) Study determined that ... from pulmonary edema to death, and that patients with CIN ...
... , , , BEIJING, July ... access to fast and efficient radiotherapy treatments with the introduction of ... ) at the Beijing Cancer Hospital. BCH is the first ... more advanced care to a greater number of patients. , ...
Cached Medicine News:Health News:St. Alexius Medical Center Named to America's Best Hospitals Rankings 2Health News:FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent 2Health News:FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent 3Health News:FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent 4Health News:PAL Health Technologies Wins State-Level Prestigious 'Employer of the Year' Award 2Health News:Fat Reduction Market in Europe to Soar Despite Economic Downturn 2Health News:PLC Medical Systems Announces Publication of Care Study Update 2Health News:PLC Medical Systems Announces Publication of Care Study Update 3Health News:Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 2Health News:Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 3
... It's easy on delicate urethral ... and hydrophilic coating provide nearly ... gel. It's easy to maintain ... catheter with its own sterile ...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
The Gizmo male external catheter is a latex catheter that uses a single-sided adhesive strip....
... Medical's line of Personal ... catheters you would choose ... product configurations - standard, ... hydro - are based ...
Medicine Products: